23.90SEK-3.43%Mkt Cap: 705.76M SEKP/E: 56.90Last update: 2026-06-01
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatien…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap705.76M SEK
Enterprise Value—
Revenue (TTM)31.84M SEK
Gross Profit162.84M SEK
Net Income (TTM)12.54M SEK
Revenue/Share14.65 SEK
Last Price23.90 SEK
Fiscal Year EndMar 2026
MR QuarterMar 2018
Employees—
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0005497732
Valuation
P/E (Trailing)56.90
P/E (Forward)7.91
PEG—
EV/EBITDA—
EV/Revenue—
P/S22.96
P/B2.74
EPS (TTM)0.42
EPS (Forward)3.13
52W Range
23.700% of range108.80
52W High108.80 SEK
52W Low23.70 SEK
Profitability
Gross Margin37.64%
Oper. Margin-16.73%
EBITDA Margin1.60%
Profit Margin2.90%
ROE4.69%
ROA1.47%
Growth
Revenue Growth21.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF28.36M SEK
CapEx (TTM)67.24M SEK
FCF Margin-69.16%
FCF Yield-3.12%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity1.82
Current Ratio2.84
Quick Ratio—
Book Value/Sh9.044 SEK
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)50.00 SEK
Target Range50.00 SEK – 50.00 SEK
# Analysts1
Ownership
Shares Out.29.53M
Float11.75M
Insiders61.09%
Institutions16.09%
Technical
SMA 5044.86 (-46.7%)
SMA 20057.23 (-58.2%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)107.75K
Avg Vol (10d)94.29K
Technical Indicators
RSI (14)23.5
MACD-6.3753
MACD Signal-6.5515
MACD Hist.+0.1762
BB Upper52.97 SEK
BB Middle32.37 SEK
BB Lower11.76 SEK
BB Width127.31%
ATR (14)2.408 SEK
Vol Ratio (20d)0.40x